BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Quest PharmaTech Inc. 

9411 20 Avenue

Edmonton  Alberta  T6N 1E5  Canada
Phone: 780-448-1400 Fax: 780-416-0324


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer 6/10/2014 8:58:58 AM
Q&A Interview With CEO Of Quest PharmaTech Inc. (TSX.V: QPT) 1/22/2014 9:48:13 AM
Quest PharmaTech Inc. Strengthens its Antibody Immunotherapy Technology by Licensing Anti-Muc1 IGE Technology From Stanford University; Researchers to Present Late-Breaking Data at the 28th Annual Meeting of the Society For Immunotherapy of Cancer to be Held November 8 - 10, 2013 In Maryland, U.S. 11/7/2013 10:47:54 AM
Quest PharmaTech Inc. Establishes Joint Venture With Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer 7/23/2013 10:24:21 AM
Quest PharmaTech Inc. Signs Exclusive License Agreement With University of California, Los Angeles (UCLA) for Anti - PSA IgE Technology; UCLA researchers to Present Anti - PSA IgE Preclinical Data at the 2013 American Association for Cancer Research Conference 4/9/2013 9:43:30 AM
Quest PharmaTech Inc. Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S. 1/22/2013 10:32:05 AM
Quest PharmaTech Inc. Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy 7/10/2012 9:33:21 AM
Quest PharmaTech Inc. Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States 6/14/2012 11:15:55 AM
Quest PharmaTech Inc. Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs 6/6/2012 10:23:06 AM
Quest PharmaTech Inc. Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology 11/29/2011 12:42:31 PM
12345